Back

Safety of non-vitamin K antagonist oral anticoagulants: concerns in patients with atrial fibrillation and glomerular hyperfiltration?

European Heart Journal

19 August 2022
Organised by: Logo
Read full article
ESC Journals

Contributors

Alda Huqi
Alda Huqi

Author

Carmine Zoccali
Carmine Zoccali

Author

Robert P Giugliano
Robert P Giugliano

Author

Brigham and Women's Hospital Boston , United States of America

Raffaele De Caterina
Raffaele De Caterina

Author

University of Pisa Pisa , Italy

You may be interested in
thumbnail
Congress Presentation
Non-vitamin K antagonist oral anticoagulants are safe and effective alternatives to warfarin across subgroups by renal function: results from Danish registries
2 September 2019
thumbnail
Congress Session
Stroke and bleeding risk in atrial fibrillation: walking the tight rope
25 August 2023
thumbnail
Congress Presentation
What if your patient with AF has CKD?
3 April 2022
thumbnail
Congress Presentation
Direct oral anticoagulants, all-cause mortality and cardiovascular events in patients with atrial fibrillation with and without obesity: a sub-analysis of the nationwide START registry.
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources